Ever since the introduction of the Steritas Glucocorticoid Toxicity Index (GTI) in 2017, there has been a remarkable surge in the number of clinicians and clinical researchers using Steritas's growing suite of steroid-toxicity assessment tools. Over the past six months, adoption has continued to grow at an exponential rate.

In March this year, we reported the Steritas eCOA suite had been used in more than 70 clinical trials, in 600 sites spread across 80 countries.

Today, Steritas instruments have been adopted across more than 1000 trial and clinic sites. 

Growth in Steritas Instrument Usage in Trials and the Clinic

This surge in demand reflects the growing recognition of the importance of steroid-toxicity assessment in both pharmaceutical research and clinical practice. Glucocorticoids are amongst the most prescribed medications in the world, with 50 million people, or 1% of the world's adult population taking them long-term.[1] They are both a panacea and a poison and the toxicities associated with their usage can be likened to an epidemic.

Usage to date

The GTI, its pediatric sibling the pGTI and the recently introduced GTI-MD, have now been used in more than 25 disease indications, including (but not limited to):

Asthma

Autoimmune blistering diseases

Bullous pemphigoid

Pemphigus foliaceus

Pemphigus vulgaris 

Congenital adrenal hyperplasia

Idiopathic Inflammatory Myopathies

Dermatomyositis

Inflammatory myopathy

 
IgG4-Related Disease
 
Inflammatory Arthritis

Juvenile idiopathic arthritis (pediatric)

Rheumatoid arthritis

Interstitial lung disease

Myasthenia gravis
 
Primary Glomerular Diseases
  
Minimal change disease (pediatric)

Nephrotic syndrome

Primary membranous nephropathy and podocytopathies

Sarcoidosis

Cardiac

Pulmonary

 
Systemic lupus erythematosus (SLE)

Lupus nephritis
Pediatric lupus nephritis

 
Vasculitis

Aortitis

Behcet’s Disease

Giant cell arteritis (GCA)

Granulomatosis with polyangiitis (GPA)

Kawasaki’s disease (pediatric)

Microscopic polyangiitis (MPA)

Polymyalgia rheumatica (PMR)

Takayasu’s arteritis

With this rapid growth in adoption, it's perhaps no surprise that Steritas was recently named Start-Up of the Year at the 2023 SAMPS Awards. The annual SAMPS Awards celebrate companies doing important work in the life sciences, and Steritas was recognized among dozens of the best that the industry has to offer.

Laura Haldane of SciLeads presented the award, recognizing Steritas’ support of scientific rigor in clinical trials by quantifying steroid-toxicity to enable the development of steroid-sparing therapies, to change steroid-prescribing patterns across health systems, and to empower patients to engage in their own care. 

References

1. Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatol Oxf Engl. 2011;50:1982–1990.